148 related articles for article (PubMed ID: 38245540)
1. A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors.
Hook C; Chatterjee U; Sheng H; Zhu Q; Robinson T; Roh JM; Laurent CA; Lee C; Delmerico J; Lo JC; Ambrosone CB; Kushi LH; Kwan ML; Yao S
NPJ Breast Cancer; 2024 Jan; 10(1):9. PubMed ID: 38245540
[TBL] [Abstract][Full Text] [Related]
2. Improved prediction of fracture risk leveraging a genome-wide polygenic risk score.
Lu T; Forgetta V; Keller-Baruch J; Nethander M; Bennett D; Forest M; Bhatnagar S; Walters RG; Lin K; Chen Z; Li L; Karlsson M; Mellström D; Orwoll E; McCloskey EV; Kanis JA; Leslie WD; Clarke RJ; Ohlsson C; Greenwood CMT; Richards JB
Genome Med; 2021 Feb; 13(1):16. PubMed ID: 33536041
[TBL] [Abstract][Full Text] [Related]
3. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
4. Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
J Bone Miner Res; 2019 Aug; 34(8):1428-1435. PubMed ID: 31069862
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
6. A Polygenic Risk Score as a Risk Factor for Medication-Associated Fractures.
Manousaki D; Forgetta V; Keller-Baruch J; Zhao K; Greenwood CM; Mooser V; Bassett JD; Leslie WD; Richards JB
J Bone Miner Res; 2020 Oct; 35(10):1935-1941. PubMed ID: 32511779
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
8. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
[TBL] [Abstract][Full Text] [Related]
10. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
11. DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study.
Rouach V; Greenman Y; Chodick G; Goldshtein I
J Bone Oncol; 2023 Oct; 42():100501. PubMed ID: 37664159
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
13. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
14. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Ouédraogo AM; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels DN; Chan KKW; Earle CC
Breast; 2021 Dec; 60():295-301. PubMed ID: 34728119
[TBL] [Abstract][Full Text] [Related]
15. The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy.
Monteverdi S; Pedersini R; Gallo F; Maffezzoni F; Dalla Volta A; Di Mauro P; Turla A; Vassalli L; Ardine M; Formenti AM; Simoncini EL; Giustina A; Maroldi R; Amoroso V; Berruti A
JBMR Plus; 2021 Feb; 5(2):e10440. PubMed ID: 33615109
[TBL] [Abstract][Full Text] [Related]
16. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
[TBL] [Abstract][Full Text] [Related]
17. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
18. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
[TBL] [Abstract][Full Text] [Related]
19. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao S; Laurent CA; Roh JM; Lo J; Tang L; Hahn T; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
[TBL] [Abstract][Full Text] [Related]
20. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
